pbo, with a mkt cap of $16m, & some great technologies in developement have been a takeover target for a while, imo.
In Bioshares this week, it mentions that all three biotech takeovers announced last week targeted revenue generating companies.
Here's a quote:
"One likelihood is that if and when Panbio becomes consistently profitable it would emerge as a takeover target for a large international profitable business seeking access to Panbio's customer base".
pbo has been cash positive for the last four quarters & will post a (modest) profit for fy05.
Their statement seems to ignor pbo's technologies, which are very good, including some of the worlds best diagnostic tests for the likes of dengue fever.
It should be an interesting year ahead.
PBO
panbio limited
